Stocksigma LogoStocksigma Logo

Alkem Laboratories Reports Q2FY27 Results with 13.8% Revenue Growth

Alkem Laboratories reported Q2FY27 revenue of ₹45,520 mn, up 13.8% YoY, supported by India sales growing 9.5% YoY to ₹30,275 mn and international sales

Alkem Laboratories Reports Q2FY27 Results with 13.8% Revenue Growth

Alkem Laboratories Ltd · Investor Presentation · 12 Nov 2026, 7:28 pm

Alkem Laboratories Reports Q2FY27 Results with 13.8% Revenue Growth Alkem Laboratories reported Q2FY27 revenue of ₹45,520 mn, up 13.8% YoY, supported by India sales growing 9.5% YoY to ₹30,275 mn and international sales surging 22.3% YoY to ₹14,540 mn. EBITDA rose 11.3% YoY to ₹10,252 mn with margins contracting 50 bps YoY to 22.5% due to Enzene CDMO operating costs and Occlutech integration. PAT dropped 11.7% YoY to ₹6,753 mn on higher effective taxes. Net cash stood at ₹49,054 mn as of 30th Sep'26. Mandva API facility cleared US FDA inspection with zero observations.

Original exchange filing (PDF)

More announcements from Alkem Laboratories Ltd

All Alkem Laboratories Ltd announcements